EVO:NASDAQ
Evotec SE
US$2.94
0.00%
(0.00) 1 天
US$3.00
arrow_upward
+2.04% (+0.060)today开盘前
休市： 4月29日, GMT-4 16:00:00 · USD
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 EVO 生成关键数据洞见…
市值
一〇.五六亿
平均成交量
一一.九四万
成交量
四一六三.〇〇
52 周最高价
US$4.80
52 周最低价
US$2.31
每股收益
-US$0.34
Beta 版
一.九〇
流通股数
三.五六亿
员工人数
四四六七
新闻报道
来自全网
AD HOC NEWS
·
2小时前
Evotec SE Stock (DE0005664809): Q1 2026 Results Due Today
Investing.com
·
15小时前
Evotec nominates Wolfgang Hofmann to supervisory board
资料
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Evotec SE简介